How cost-effective are new cancer drugs in the U.S.?

References

• National Cancer Institute. Drugs approved for different types of cancer. [ cited 2019 Dec 7]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/cancer-type
   Google Scholar
• Food and Drug Administration. Drugs@FDA database. [ cited 2019 Dec 7]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/about-drugsfda
   Google Scholar
• Food and Drug Administration. Review designation policy: priority (P) and standard (S). 2019 [cited 2019 Dec 7]. Available from: https://www.fda.gov/media/72723/download
   Google Scholar
• National Cancer Institute. Cancer screening overview. [ cited 2019 Dec 7]. Available from: https://www.cancer.gov/about-cancer/screening/hp-screening-overview-pdq
   Google Scholar
• Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101–121.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Compressed mortality database. [ cited 2019 Dec 7]. https://wonder.cdc.gov/mortSQL.html
   Google Scholar
• National Cancer Institute. SEER research data. [ cited 2019 Dec 7]. Available from: https://seer.cancer.gov/data/
   Google Scholar
• National Cancer Institute. SEER• Stat Software. [ cited 2019 Dec 7]. Available from: https://seer.cancer.gov/seerstat/
   Google Scholar
• Agency for Healthcare Research and Quality. HCUPnet: A tool for identifying, tracking, and analyzing national hospital statistics. [ cited 2019 Dec 7]. Available from: https://hcupnet.ahrq.gov/#setup
   Google Scholar
• Centers for Disease Control and Prevention. WISQARS years of Potential Life Lost (YPLL) Report, 1999 and later. [ cited 2019 Dec 7]. Available from: https://webappa.cdc.gov/sasweb/ncipc/ypll10.html
   Google Scholar
• IMS Institute for Healthcare Informatics. Medicines use and spending shifts: a review of the use of medicines in the U.S. in 2014. Parsippany NJ: IMS Institute for Healthcare Informatics. 2015 Apr.
   Google Scholar
• Herper M Inside the secret world of drug company rebates. Forbes. 2012 May 10.
   Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997–2010. J Hum Capital. 2014 Winter;8(4):432–480.
   Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000 Jul-Sep;20(3):332–342.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cost-effectiveness thresholds. [ cited 2019 Dec 7]. Available from: https://www.who.int/bulletin/volumes/94/12/15-164418/en/
   Google Scholar
• Lichtenberg FR. The impact of new drug launches on life-years lost in 2015 from 19 types of cancer in 36 countries. J Demographic Econ. 2018;84(3):309–354.
   Web of Science ®Google Scholar
• Cressman S, Browman GP, Hoch JS, et al. A time-trend economic analysis of cancer drug trials. Oncologist. 2015 Jul;20(7):729–736. [cited 2019 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492232/
   PubMed Web of Science ®Google Scholar
• Wieseler B, McGauran N, Kaiser T. New drugs: where did we go wrong and what can we do better?. BMJ. 2019;366.doi: 10.1136/bmj.I4340
   PubMedGoogle Scholar
• Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530.
   PubMed Web of Science ®Google Scholar
• Pease AM, Krumholz HM, Downing NS, et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ. 2017;357:j1680.
   PubMedGoogle Scholar
• Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179:906. [Epub ahead of print.].
   PubMed Web of Science ®Google Scholar
• Martin M. The Cambridge companion to Atheism. Cambridge companions to philosophy. Cambridge, UK: Cambridge University Press; 2007.
   Google Scholar
• Alderson P. Absence of evidence is not evidence of absence. BMJ. 2004;328(7438):476–477.
   PubMedGoogle Scholar
• Lichtenberg FR. How many life-years have new drugs saved? A 3-way fixed-effects analysis of 66 diseases in 27 countries, 2000–2013. Int Health. 2019 Sep;11(5):403–416.
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. The impact of access to prescription drugs on disability in eleven European countries. Disabil Health J. 2019 Jul;12(3):375–386.
   PubMed Web of Science ®Google Scholar
• Frieden TR. Evidence for health decision making — beyond randomized, controlled trials. N Engl J Med. 2017 Aug 3;377:465–475. [cited 2019 Dec 7]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra1614394
   PubMed Web of Science ®Google Scholar
• Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014 Feb 04;110:551–555. [cited 2019 Dec 7]. Available from: https://www.nature.com/articles/bjc2013725
   PubMed Web of Science ®Google Scholar
• Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Soc Sci Med. 2018;210:2–21. Available from: http://www.sciencedirect.com/science/article/pii/S0277953617307359
   PubMed Web of Science ®Google Scholar
• Nordhaus WD. Irving Fisher and the contribution of improved longevity to living standards. Am J Econ Sociology. 2005 Jan;64(1):367–392.
   Web of Science ®Google Scholar
• United Nations. Human Development Index (HDI) | Human development reports. 2017 Dec 7. Available from: hdr.undp.org/en/content/human-development-index-hdi
   Google Scholar
• Grossman GM, Helpman E. Innovation and growth in the global economy. Cambridge (MA): MIT Press; 1991.
   Google Scholar
• Romer PM. Endogenous technological change. J Political Econ. 1990 Oct;98(5, Pt. 2):S71–S102.
   Web of Science ®Google Scholar
• Aghion P, Howitt P. A model of growth through creative destruction. Econometrica. 1992 Mar;60(2):323–351.
   Web of Science ®Google Scholar
• Jones CI. Sources of U.S. Economic growth in a world of ideas. Am Econ Rev. 2002 Mar;92(1):220–239.
   Web of Science ®Google Scholar
• Patterson GS. The business of ideas: the highs and lows of inventing and extracting revenue from intellectual property. AuthorHouse, Bloomington, IN; 2012 Sep 14.
   Google Scholar
• Lichtenberg FR. The effect of pharmaceutical innovation on longevity: patient level evidence from the 1996–2002 medical expenditure panel survey and linked mortality public-use files. Forum Health Econ Policy. 2013 Jan;16(1):1–33.
   PubMedGoogle Scholar
• Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009. Health Policy Technol. 2014 Mar;3(1):36–58.
   Web of Science ®Google Scholar
• Dorsey ER, de Roulet J, Thompson JP, et al. Financial anatomy of biomedical research, 2003–2008. J Am Med Assoc. 2010;303(2):137–143.
   PubMed Web of Science ®Google Scholar
• Sampat BN, Lichtenberg FR. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs. 2011;30(2):332–339.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Enhancing drug discovery and development. [ cited 2019 Dec 7]. Available from: https://www.cancer.gov/research/areas/treatment/enhancing-drug-discovery
   Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009. Econ Hum Biol. 2014 Mar;13:107–127.
   PubMed Web of Science ®Google Scholar
• Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research funds. Br J Cancer. 2005 Jan 31;92(2):241–245.
   PubMed Web of Science ®Google Scholar
• Broda C, Weinstein DW. Variety growth and World Welfare. Am Econ Rev. 2004;94(2):139–144.
   Web of Science ®Google Scholar
• National Cancer Institute. Long-term trial results show no mortality benefit fromannual prostate cancer screening. 2012 Feb 17 [cited 2019 Dec 7]. Available from: https://www.cancer.gov/types/prostate/research/screening-psa-dre
   Google Scholar
• Food and Drug Administration. Real world evidence. [ cited 2019 Dec 7]. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
   Google Scholar
• National Science Foundation. U.S. Corporate R&D: volume 1: top 500 Firms in R&D by Industry Category. 2016 [cited 2019 Dec 7]. Available from: http://wayback.archive-it.org/5902/20150819114914/http:/www.nsf.gov/statistics/nsf00301/expendit.htm#intensity
   Google Scholar